These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2623329)

  • 41. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials.
    Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Askergren J; Friberg S
    Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):629-39. PubMed ID: 2493433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of tamoxifen in breast cancer.
    Gau TC
    Postgrad Med; 1985 Jun; 77(8):21-2. PubMed ID: 3839078
    [No Abstract]   [Full Text] [Related]  

  • 43. Adjuvant chemotherapy for node-negative breast cancer patients.
    Bonadonna G; Zambetti M; Valagussa P
    Recent Results Cancer Res; 1989; 115():175-9. PubMed ID: 2516350
    [No Abstract]   [Full Text] [Related]  

  • 44. Adjuvant systemic treatment of resectable breast cancer: eleven years results of a monoinstitutional chemo-hormone-immunotherapy trial.
    Rosso R; Boccardo F; Brema F; Sertoli MR; Amoroso D; Bertelli G; Pronzato P
    Anticancer Res; 1989; 9(4):1153-6. PubMed ID: 2817796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
    Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
    Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
    Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
    Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [5 years' results of a CMF protocol (methotrexate, cyclophosphamide, fluorouracil) of adjuvant chemotherapy in breast cancers].
    Horner-Vallet D; Cappelaere P; Delobelle A; Depadt G; Madelain M; Demaille A
    LARC Med; 1984 Nov; 4(9):532-40. PubMed ID: 6549038
    [No Abstract]   [Full Text] [Related]  

  • 51. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
    Ludwig Breast Cancer Study Group
    Lancet; 1984 Jun; 1(8389):1256-60. PubMed ID: 6144974
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tamoxifen versus chemotherapy as adjuvant treatment in stage III breast cancer.
    Alagaratnam TT; Wong J
    Aust N Z J Surg; 1986 Jan; 56(1):39-41. PubMed ID: 3090987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
    Parulekar WR; Day AG; Ottaway JA; Shepherd LE; Trudeau ME; Bramwell V; Levine M; Pritchard KI;
    J Clin Oncol; 2005 Sep; 23(25):6002-8. PubMed ID: 16135468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
    Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
    J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rehabilitation of patients with primary breast cancer: assessing the impact of adjuvant therapy.
    Ganz PA; Polinsky ML; Schag CA; Heinrich RL
    Recent Results Cancer Res; 1989; 115():244-54. PubMed ID: 2623333
    [No Abstract]   [Full Text] [Related]  

  • 58. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer.
    Houston SJ; Richards MA; Bentley AE; Smith P; Rubens RD
    Eur J Cancer; 1993; 29A(11):1513-8. PubMed ID: 8217354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Breast cancer staging and the "alert": an educational dilemma.
    Kennedy BJ
    J Cancer Educ; 1990; 5(2):91-7. PubMed ID: 2206937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.